These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36641121)

  • 1. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture.
    Lin YC; Chen BM; Tran TTM; Chang TC; Al-Qaisi TS; Roffler SR
    J Control Release; 2023 Feb; 354():354-367. PubMed ID: 36641121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice.
    Chang TC; Chen BM; Wu JY; Cheng TL; Roffler S
    Biomed Pharmacother; 2022 Feb; 146():112502. PubMed ID: 34891120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cell Assay for Detecting Anti-PEG Immune Response against PEG-Modified Therapeutics.
    Shimizu T; Abu Lila AS; Awata M; Kubo Y; Mima Y; Hashimoto Y; Ando H; Okuhira K; Ishima Y; Ishida T
    Pharm Res; 2018 Oct; 35(11):223. PubMed ID: 30280273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins.
    Saifer MG; Williams LD; Sobczyk MA; Michaels SJ; Sherman MR
    Mol Immunol; 2014 Feb; 57(2):236-46. PubMed ID: 24200843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
    Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
    Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
    Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
    Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
    Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
    Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
    Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
    Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
    Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
    Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
    Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
    J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
    Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
    Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies.
    Chen BM; Cheng TL; Roffler SR
    ACS Nano; 2021 Sep; 15(9):14022-14048. PubMed ID: 34469112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism.
    Elsadek NE; Emam SE; Abu Lila AS; Shimizu T; Ando H; Ishima Y; Ishida T
    Biol Pharm Bull; 2020; 43(9):1393-1397. PubMed ID: 32879214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice.
    Chang TC; Chen BM; Lin WW; Yu PH; Chiu YW; Chen YT; Wu JY; Cheng TL; Hwang DY; Roffler AS
    Pharmaceutics; 2019 Dec; 12(1):. PubMed ID: 31877813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the methoxy group in immune responses to mPEG-protein conjugates.
    Sherman MR; Williams LD; Sobczyk MA; Michaels SJ; Saifer MG
    Bioconjug Chem; 2012 Mar; 23(3):485-99. PubMed ID: 22332808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.
    Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M
    J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions.
    Kozma GT; Mészáros T; Vashegyi I; Fülöp T; Örfi E; Dézsi L; Rosivall L; Bavli Y; Urbanics R; Mollnes TE; Barenholz Y; Szebeni J
    ACS Nano; 2019 Aug; 13(8):9315-9324. PubMed ID: 31348638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
    Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
    Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.
    McSweeney MD; Price LSL; Wessler T; Ciociola EC; Herity LB; Piscitelli JA; DeWalle AC; Harris TN; Chan AKP; Saw RS; Hu P; Jennette JC; Forest MG; Cao Y; Montgomery SA; Zamboni WC; Lai SK
    J Control Release; 2019 Oct; 311-312():138-146. PubMed ID: 31454530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.